FGF-19 human
SIGMA/SRP4542 - recombinant, expressed in E. coli, ≥95% (SDS-PAGE)
Synonym: FGF19; FGFJ; fibroblast growth factor 19
Product Type: Chemical
| assay | ≥95% (SDS-PAGE) |
| biological source | human |
| form | lyophilized |
| impurities | endotoxin, tested |
| mol wt | ~21.8 kDa |
| NCBI accession no. | NM_005117   |
| packaging | pkg of 25 μg |
| potency | 50-200 ng/mL |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| UniProt accession no. | O95750 |
| Biochem/physiol Actions: | Fibroblast growth factor-19 (FGF-19) is involved in the gut-liver signaling pathway and modulation of bile acid synthesis. Once secreted, it binds to the hepatic fibroblast growth factor receptor 4 (FGFR4)/Klotho-β cell-surface receptor complex and activates it. FGF-19 promotes glycogen synthesis, protein synthesis and lipid metabolism. |
| General description: | Fibroblast growth factor-19 (FGF-19) is an ileum-derived polypeptide hormone and a high affinity heparin-dependent ligand for fibroblast growth factor receptor 4 (FGFR4). It is part of the hormone-like FGF family. The gene encoding FGF-19 is localized on human chromosome 11q13.3. Recombinant human FGF-19 is a 21.8kDa protein containing 195 amino acid residues. |
| Physical form: | Lyophilized from 5 mM Tris, pH 7.6 plus 75 mM NaCl. The protein may appear as a haze or film, which you may not see at the bottom of the vial. |
| Reconstitution: | Centrifuge the vial prior to opening. Avoid freeze-thaw cycles. |
| Reconstitution: | Reconstitute in water to a concentration of 0.1 to 1.0 μg/μL. This solution can then be diluted into other aqueous buffers. |
| WGK Germany | 3 |
| Purity | ≥95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |